IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Clinical trial NCT05059470 · TERMINATED
Trial details
- NCT number
- NCT05059470
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-11
- Primary completion
- 2025-07-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.